Group 1 - The company has entered into three subscription agreements with different subscribers, agreeing to issue a total of 1.43 billion shares at a subscription price of HKD 0.097 per share, raising a total of HKD 1.55 billion [1][2] - The first agreement involves the issuance of 30 million shares for a total of HKD 2.91 million, the second agreement involves 20 million shares for HKD 1.94 million, and the third agreement involves 110 million shares for HKD 10.67 million [1] - The subscription matters are conditional and will only be finalized upon the fulfillment of specified conditions [1] Group 2 - The net proceeds from the subscription will be used to develop potential new business in health products, equipment, and technology trade, manufacturing, sales, and distribution in China, as well as to expand related business opportunities overseas [2] - The company believes that the demand for products and solutions that improve health and patient care will continue to grow due to factors such as an aging population, increasing prevalence of chronic diseases, heightened health awareness, and technological advancements [2] - The net proceeds will support the company in seizing new business opportunities more effectively [2]
精优药业(00858)拟配发合共1.6亿股 净筹款项用于新业务发展